Alameda, Calif.-based OncoCyte Corp. is looking to raise $3.6 million via an offering of units.
The company entered into an agreement with certain investors led by its management and board as well as new institutional investors for the purchase of the units.
The units are being offered at an at-market purchase price per unit of $2.86 per share and will consist of 1 common share and a common share purchase warrant. The warrants are exercisable at $3 per share six months after issuance and have a term of five years.
OncoCyte intends to use the proceeds to develop its lung cancer diagnostic test, DetermaVu, and other general corporate purposes.
The offering is expected to close July 31, subject to customary closing conditions.
Chardan is acting as the exclusive placement agent for the offering.
OncoCyte focuses on the discovery, development and commercialization of noninvasive blood and urine diagnostic tests for the early detection of cancer.